Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Amicus Therapeutics raises $55mm with Series C round
05 Oct 2005
Amicus Therapeutics (develops small-molecule drugs for genetic disorders) raised $55mm through a Series C financing round led by Quaker BioVentures. Also participating in the round were other new backers Palo Alto Investors and the Garden State Life Sciences Venture Fund (managed by the New Jersey Economic Development Authority), and existing shareholders Canaan Partners, CHL Medical Partners, Frazier Healthcare Ventures, New Enterprise Associates, Prospect Venture Partners, and Radius Ventures.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?